Saturday 17 October 2026
Export STOK’s income statement to Excel — free account
Stoke Therapeutics, Inc.
STOK Healthcare Biotechnology
Stoke Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $184.4 million, up 404.5% from fiscal 2024. In the quarter to June 2026, revenue fell 32.5%, EPS fell 132.5% and free cash flow fell 129.0%, each against the same quarter a year earlier.
24.17
0.44
−1.79%
Follow STOK
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | |
|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
5 | 4 | — | — | — | — | — | — | — |
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | — | — | — | — | — |
Altman Z-Score |
16.42 | 5.63 | (1.10) | 1.10 | — | — | — | — | — |
P/S ratio |
10.19 | 16.30 | 29.36 | 28.50 | — | — | — | — | — |
P/FCF ratio |
41.85 | 0.00 | 0.00 | 0.00 | — | — | — | — | — |
Altman Z″-Score (non-manufacturers) |
5.29 | 1.91 | (1.38) | 1.65 | — | — | — | — | — |
P/Operating CF |
(61.72) | (25.69) | (12.49) | (15.80) | — | — | — | — | — |
Beneish M-Score |
0.76 | 9.04 | (3.96) | — | — | — | — | — | — |
P/B ratio |
5.33 | 2.60 | 1.62 | 1.91 | — | — | — | — | — |
Price to Tangible BV |
5.33 | 2.60 | 1.62 | 1.91 | — | — | — | — | — |
EV/Sales |
8.65 | 10.36 | 6.43 | 9.99 | — | — | — | — | — |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | — | — | — | — | — |
EV/Operating CF |
34.99 | (4.36) | (0.70) | (3.89) | — | — | — | — | — |
EV/FCF |
35.51 | (4.35) | (0.68) | (3.46) | — | — | — | — | — |
Quick Ratio |
5.06 | 5.48 | 6.54 | 7.33 | 12.83 | 25.15 | 54.32 | 42.80 | 0.48 |
Current Ratio |
5.28 | 5.81 | 6.99 | 7.77 | 13.37 | 25.73 | 55.12 | 43.03 | 0.51 |
Net Debt/EBITDA |
14.29 | 2.15 | 1.79 | 2.23 | 2.59 | 5.51 | 6.32 | 8.39 | (0.22) |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (2.32) |
Asset Turnover |
0.53 | 0.15 | 0.04 | 0.05 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF/Net income |
(6.62) | 0.98 | 0.77 | 0.32 | 0.78 | 0.81 | 0.96 | 0.88 | 0.97 |
Capex/Depreciation |
(1.05) | (0.38) | (0.75) | (2.97) | (1.07) | (1.18) | (3.63) | (4.32) | 0.00 |
Interest Coverage |
— | — | — | — | — | — | — | — | (526.95) |
| (2.37%) | (45.80%) | (60.80%) | (50.20%) | (34.06%) | (20.47%) | (19.62%) | (24.13%) | (10.71%) | |
| (2.00%) | (35.60%) | (43.23%) | (40.84%) | (31.97%) | (19.84%) | (19.22%) | (23.29%) | (10.11%) | |
ROIC |
(19.12%) | (525.92%) | 0.00% | 0.00% | 0.00% | 0.00% | (1,139.44%) | 0.00% | 0.00% |
Return on Tangible Assets |
(2.74%) | (45.26%) | (55.01%) | (46.08%) | (39.68%) | (18.32%) | (14.40%) | (11.94%) | 417.27% |
Average Days of Receivables |
15.65 | 23.64 | 2.66 | 17.30 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Research and Development Expense of Revenue |
74.79% | 243.83% | 936.57% | 627.46% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
36.38% | 133.48% | 470.64% | 313.78% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
17.48% | 75.15% | 287.67% | 184.23% | 0.00% | 0.00% | 0.00% | 0.00% | — |
Graham Net Nets |
0.13 | 0.32 | 0.57 | 0.49 | — | — | — | — | — |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | — | — | — | — | — |
Earnings Yield |
(0.32%) | (15.23%) | (40.44%) | (28.60%) | — | — | — | — | — |
Free Cash Flow Yield |
2.39% | (14.61%) | (32.07%) | (10.13%) | — | — | — | — | — |
Revenue per Share |
3.11 | 0.68 | 0.20 | 0.32 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF per Share |
0.77 | (1.61) | (1.84) | (0.82) | (1.82) | (1.26) | (1.73) | (15.46) | (0.16) |
Capex per Share |
(0.01) | 0.00 | (0.04) | (0.10) | (0.03) | (0.03) | (0.09) | (1.30) | 0.00 |
Free Cash Flow per Share |
0.76 | (1.61) | (1.88) | (0.92) | (1.85) | (1.29) | (1.82) | (16.76) | (0.16) |
Cash per Share |
4.82 | 4.02 | 4.58 | 5.90 | 5.98 | 8.58 | 12.38 | 148.60 | 0.06 |
Shareholders Equity per Share |
5.95 | 4.24 | 3.63 | 4.75 | 5.93 | 8.54 | 12.49 | 148.13 | (0.04) |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
5.95 | 4.24 | 3.63 | 4.75 | 5.93 | 8.54 | 12.49 | 148.13 | (0.04) |
Free Cash Flow |
44.92 | (87.05) | (82.68) | (35.83) | (68.11) | (43.27) | (32.69) | (11.89) | (5.38) |
Working Capital |
247.83 | 192.70 | 184.52 | 212.68 | 212.08 | 282.51 | 221.93 | 103.68 | (1.80) |
Capital Expenditures |
(0.67) | (0.20) | (1.62) | (3.96) | (1.20) | (1.05) | (1.63) | (0.92) | (0.11) |
Net Current Asset Value |
239.72 | 190.22 | 146.56 | 172.85 | 208.13 | 282.08 | 221.71 | 103.67 | (1.82) |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | — | — | — | — | — |
Capex to Sales |
0.00 | 0.01 | 0.18 | 0.32 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | — | — | — | — | — |
| Other line items | |||||||||
Depreciation/Fixed assets |
0.20 | 0.14 | 0.37 | 0.20 | 0.27 | 0.33 | 0.18 | 0.18 | 0.24 |
Cash ROIC |
7.04% | (19.52%) | (22.91%) | (8.64%) | (15.56%) | (7.55%) | (7.31%) | (5.65%) | (153.61%) |
Accounts Receivable Turnover |
35.90 | 30.06 | 26.93 | 34.46 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.19 |
Inventory Turnover |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 455.44 |
Days of Inventory on Hand |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Average Receivables |
5.14 | 1.22 | 0.33 | 0.36 | 0.07 | 0.14 | 0.24 | 0.24 | — |
Average Payables |
3.72 | 2.10 | 1.23 | 1.58 | 1.94 | 1.12 | 0.91 | 0.61 | 0.61 |
Average Assets |
344.99 | 249.95 | 242.20 | 247.47 | 268.40 | 263.34 | 168.14 | 53.77 | 54.99 |
Average Common Equity |
290.74 | 194.29 | 172.21 | 201.31 | 251.93 | 255.25 | 164.75 | 51.88 | 51.87 |
Columns are period end dates